Cytoo to Spend $10M in New Funding on R&D, Marketing Activities | GenomeWeb

By Justin Petrone

Cytoo will use the proceeds from its most recent round of financing to fund several R&D projects and expand its marketing activities, with the hope of attracting more interest from pharmaceutical customers, according to its CEO.

Francois Chatelain told BioArray News this week that the developer of micropattern array technology for cell-based assays raised the $10 million in series C financing to "aggressively do R&D and innovation" and to "beef up" its marketing efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.